SCHEMBL8520679

SCHEMBL8520679

O=C(O)c1c(OCc2ccccc2)cc(-c2ccccc2)n2ncnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 1/20 0.43
PTGER1 P34995 3/20 0.41
MDM2 Q00987 1/20 0.41
PTGER4 P35408 2/20 0.40
PTGER3 P43115 2/20 0.40
PTGER2 P43116 2/20 0.40
FOLH1 Q04609 2/20 0.40
MAP4K4 O95819 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
EGLN1 Q9GZT9 2/20 0.39
PTPN1 P18031 1/20 0.39
MCL1 Q07820 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8526969 0.86 EGLN2 (0.39) EGLN2PTGER1PTGER4PTGER3PTGER2
SCHEMBL8520790 0.84 RIPK1 (0.41) EGLN2PTGER1RXRARXRBRXRG
SCHEMBL30599268 0.81 NR4A2 (0.40) FOLH1MCL1EGFRERBB2MEN1
SCHEMBL31563011 0.81 RXRB (0.33) PTGER1FOLH1MAP4K4RXRARXRB
SCHEMBL12750387 0.80 FOLH1 (0.37) EGLN2PTGER1FOLH1MAP4K4EGLN1
SCHEMBL8517219 0.79 PTGER1 (0.47) PTGER1PTGER4PTGER3PTGER2FOLH1
SCHEMBL12828684 0.76 MRGPRX4 (0.40) EGLN1
SCHEMBL8520796 0.74 NR1H2 (0.39) EGLN2PTGER1
SCHEMBL12750427 0.73 PPIA (0.43) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL8552187 0.72 PTGER1 (0.43) PTGER1FOLH1EGLN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN2 3/4885PTGER1 1511/4885MDM2 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.